Cipla enters into strategic partnership with SIGA Technologies to fight against biothreats

Cipla Therapeutics (a division of Cipla USA, Inc., an affiliate of Cipla Ltd) has entered into a strategic partnership with SIGA Technologies to deliver sustained innovation and access to novel antibacterial drugs, particularly against biothreats. 

This strategic collaboration will provide solutions for biothreats along with other public health needs to Biomedical Advanced Research & Development Authority (BARDA), a US Department of Health and Human Services (HHS). 

SIGA has secured multiple contracts awarded by the US Government over a period of more than 10 years that provide for the development and procurement of up to approximately USD 1 billion for the supply and re-supply of TPOXX in the Strategic National Stockpile. 

Cipla is committed to addressing the AMR challenge and also, owns & markets the novel antibiotic Zemdri (Plazomicin) injection in the United States. It has a global footprint including a 3,50,000 square foot manufacturing facility in Long Island, New York. 

This partnership provides an opportunity for the US Government agencies such as BARDA to advance preparation and health security programme initiatives with the novel antibiotic, Zemdri while working through a known partner in SIGA, an entity with deep expertise in USG contracting and BARDA’s hands-on approach to advanced development. 

On Tuesday, the stock of Cipla opened 0.8 per cent higher at Rs 779 from its previous close of Rs 772.80 on BSE.